Esperion Therapeutics

$28.67
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.13 (+4.13%) Today
+$0.15 (+0.53%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ESPR and other stocks, options, and ETFs commission-free!

About ESPR

Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI. The listed name for ESPR is Esperion Therapeutics, Inc. Common Stock.

CEO
Tim M. Mayleben
Employees
479
Headquarters
Ann Arbor, Michigan
Founded
1998
Market Cap
800.79M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
836.63K
High Today
$28.72
Low Today
$27.50
Open Price
$28.46
Volume
679.64K
52 Week High
$56.85
52 Week Low
$23.90

ESPR Earnings

-$3.89
-$1.15
$1.58
$4.32
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$3.76 per share
Actual
-$3.89 per share
Replay Earnings Call

You May Also Like

PDFS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure